Airflow obstruction, lung function, and incidence of atrial fibrillation: The atherosclerosis risk in communities (ARIC) study

Circulation

Volumn 129, Issue 9, 2014, Pages 971-980

  Li, Jingjing ^a   Agarwal, Sunil K ^b   Alonso, Alvaro ^c   Blecker, Saul ^d   Chamberlain, Alanna M ^e   London, Stephanie J ^f   Loehr, Laura R ^a   McNeill, Ann Marie ^a   Poole, Charles ^a   Soliman, Elsayed Z ^g   Heiss, Gerardo ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e MAYO CLINIC   (United States)

^f NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^g WAKE FOREST UNIVERSITY   (United States)

Author keywords

atrial fibrillation; chronic obstructive; forced expiratory volume; pulmonary disease; respiratory physiological phenomena; risk factors; vital capacity

Indexed keywords

ALBUMIN; FIBRINOGEN;

ADULT; AIRWAY OBSTRUCTION; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CAUCASIAN; COHORT ANALYSIS; DEATH CERTIFICATE; DISEASE ASSOCIATION; EDUCATIONAL STATUS; ELECTROCARDIOGRAM; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; LEUKOCYTE COUNT; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIDDLE AGED; NEGRO; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; SMOKING; SPIROMETRY;

ATRIAL FIBRILLATION; FORCED EXPIRATORY VOLUME; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY PHYSIOLOGICAL PHENOMENA; RISK FACTORS; VITAL CAPACITY;

AFRICAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; LUNG; LUNG DISEASES, OBSTRUCTIVE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SPIROMETRY;

EID: 84895521466     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.004050     Document Type: Article

References (45)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C. Heart disease and stroke statistics: 2010 update. Circulation. 2010;121:e46-e215.
2. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946-952.
3. Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, Maclehose R, Konety S, Alonso A. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123:1501-1508.
4. Benjamin EJ, Chen PS, Bild DE, Mascette AM, Albert CM, Alonso A, Calkins H, Connolly SJ, Curtis AB, Darbar D, Ellinor PT, Go AS, Goldschlager NF, Heckbert SR, Jalife J, Kerr CR, Levy D, Lloyd-Jones DM, Massie BM, Nattel S, Olgin JE, Packer DL, Po SS, Tsang TS, Van Wagoner DR, Waldo AL, Wyse DG. Prevention of atrial fibrillation: report from a National Heart, Lung, and Blood Institute workshop. Circulation. 2009;119:606-618.
5. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005;127:1952-1959.
6. Agarwal SK, Heiss G, Barr RG, Chang PP, Loehr LR, Chambless LE, Shahar E, Kitzman DW, Rosamond WD. Airflow obstruction, lung function, and risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study. Eur J Heart Fail. 2012;14:414-422.
7. Truelsen T, Prescott E, Lange P, Schnohr P, Boysen G. Lung function and risk of fatal and non-fatal stroke: the Copenhagen City Heart Study. Int J Epidemiol. 2001;30:145-151.
8. Hozawa A, Billings JL, Shahar E, Ohira T, Rosamond WD, Folsom AR. Lung function and ischemic stroke incidence: the Atherosclerosis Risk in Communities study. Chest. 2006;130:1642-1649.
9. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271:840-844.
10. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, White R, Furberg CD, Rautaharju PM. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96:2455-2461.
11. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart. 2001;86:516-521.
12. Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J. 2003;21:1012-1016.
13. Soliman EZ, Prineas RJ, Case LD, Zhang ZM, Goff DC Jr. Ethnic distribution of ECG predictors of atrial fibrillation and its impact on understanding the ethnic distribution of ischemic stroke in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2009;40:1204-1211.
14. The Atherosclerosis Risk in Communities (ARIC) study: design and objectives: the ARIC Investigators. Am J Epidemiol. 1989;129:687-702.
15. Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, Prineas RJ, Folsom AR. Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2009;158:111-117.
16. Gronroos NN, Chamberlain AM, Folsom AR, Soliman EZ, Agarwal SK, Nettleton JA, Alonso A. Fish, fish-derived n-3 fatty acids, and risk of incident atrial fibrillation in the Atherosclerosis Risk in Communities (ARIC) study. PLoS One. 2012;7:e36686.
17. White AD, Folsom AR, Chambless LE, Sharret AR, Yang K, Conwill D, Higgins M, Williams OD, Tyroler HA. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. J Clin Epidemiol. 1996;49:223-233.
18. Atherosclerosis Risk in Communities Study Manual 4: Pulmonary Function. Chapel Hill, NC: Chapel Hill NNH, Lung, and Blood Institute of the National Institutes of Health, Collaborative Studies Coordinating Center, University of North Carolina; 1987.
19. ATS statement:-snowbird workshop on standardization of spirometry. Am Rev Respir Dis. 1979;119:831-838.
20. Ferris BG. Epidemiology standardization project (American Thoracic Society). Am Rev Respir Dis. 1978;118(pt 2):1-120.
21. Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care. 2001;46:798-825.
22. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32:962-969.
23. Smith BM, Kawut SM, Bluemke DA, Basner RC, Gomes AS, Hoffman E, Kalhan R, Lima JA, Liu CY, Michos ED, Prince MR, Rabbani L, Rabinowitz D, Shimbo D, Shea S, Barr RG. Pulmonary hyperinflation and left ventricular mass: the Multi-Ethnic Study of Atherosclerosis COPD Study. Circulation. 2013;127:1503-1511, 1511e1.
24. Eriksson H, Caidahl K, Larsson B, Ohlson LO, Welin L, Wilhelmsen L, Svärdsudd K. Cardiac and pulmonary causes of dyspnea: validation of a scoring test for clinical-epidemiological use: the Study of Men Born in 1913. Eur Heart J. 1987;8:1007-1014.
25. Govindarajulu US, Spiegelman D, Thurston SW, Ganguli B, Eisen EA. Comparing smoothing techniques in Cox models for exposure-response relationships. Stat Med. 2007;26:3735-3752.
26. Vollmer WM, Johnson LR, McCamant LE, Buist AS. Methodologic issues in the analysis of lung function data. J Chronic Dis. 1987;40:1013-1023.
27. Shibata Y, Watanabe T, Osaka D, Abe S, Inoue S, Tokairin Y, Igarashi A, Yamauchi K, Kimura T, Kishi H, Aida Y, Nunomiya K, Nemoto T, Sato M, Konta T, Kawata S, Kato T, Kayama T, Kubota I. Impairment of pulmonary function is an independent risk factor for atrial fibrillation: the Takahata study. Int J Med Sci. 2011;8:514-522.
28. Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Métayer P, Clémenty J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339:659-666.
29. Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA, Jiang R, Kawut SM, Kronmal RA, Lima JA, Shahar E, Smith LJ, Watson KE. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010;362:217-227.
30. Smith BM, Prince MR, Hoffman EA, Bluemke DA, Liu CY, Rabinowitz D, Hueper K, Parikh MA, Gomes AS, Michos ED, Lima JA, Barr RG. Impaired left ventricular filling in COPD and emphysema: is it the heart or the lungs? The Multi-Ethnic Study of Atherosclerosis COPD Study. Chest. 2013;144:1143-1151.
31. Ryu JH, Krowka MJ, Pellikka PA, Swanson KL, McGoon MD. Pulmonary hypertension in patients with interstitial lung diseases. Mayo Clin Proc. 2007;82:342-350.
32. Alonso A, Tang W, Agarwal SK, Soliman EZ, Chamberlain AM, Folsom AR. Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: the ARIC study. Int J Cardiol. 2012;155:217-222.
33. Everett I, Thomas H, Olgin JE. Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm. 2007;4:S24-S27.
34. Kalifa J, Jalife J, Zaitsev AV, Bagwe S, Warren M, Moreno J, Berenfeld O, Nattel S. Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. Circulation. 2003;108:668-671.
35. Barbu C, Iordache M, Man MG. Inflammation in COPD: pathogenesis, local and systemic effects. Rom J Morphol Embryol. 2011;52:21-27.
36. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol. 2007;50:2021-2028.
37. Sata N, Hamada N, Horinouchi T, Amitani S, Yamashita T, Moriyama Y, Miyahara K. C-reactive protein and atrial fibrillation: is inflammation a consequence or a cause of atrial fibrillation? Jpn Heart J. 2004;45:441-445.
38. Ozaydin M. Atrial fibrillation and inflammation. World J Cardiol. 2010;2: 243-250.
39. Rienstra M, Sun JX, Magnani JW, Sinner MF, Lubitz SA, Sullivan LM, Ellinor PT, Benjamin EJ. White blood cell count and risk of incident atrial fibrillation (from the Framingham Heart Study). Am J Cardiol. 2012;109:533-537.
40. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, Tracy RP, Van Wagoner DR, Psaty BM, Lauer MS, Chung MK. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003;108:3006-3010.
41. Müllerova H, Chigbo C, Hagan GW, Woodhead MA, Miravitlles M, Davis KJ, Wedzicha JA. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med. 2012;106:1124-1133.
42. Corrales-Medina VF, Musher DM, Wells GA, Chirinos JA, Chen L, Fine MJ. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation. 2012;125:773-781.
43. Boucher KM, Slattery ML, Berry TD, Quesenberry C, Anderson K. Statistical methods in epidemiology: a comparison of statistical methods to analyze dose-response and trend analysis in epidemiologic studies. J Clin Epidemiol. 1998;51:1223-1233.
44. Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY, Soliman EZ, Astor BC, Coresh J. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123:2946-2953.
45. Benjamin EJ, Rice KM, Arking DE, Pfeufer A, van Noord C, Smith AV, Schnabel RB, Bis JC, Boerwinkle E, Sinner MF, Dehghan A, Lubitz SA, D'Agostino RB Sr, Lumley T, Ehret GB, Heeringa J, Aspelund T, Newton-Cheh C, Larson MG, Marciante KD, Soliman EZ, Rivadeneira F, Wang TJ, Eiríksdottir G, Levy D, Psaty BM, Li M, Chamberlain AM, Hofman A, Vasan RS, Harris TB, Rotter JI, Kao WH, Agarwal SK, Stricker BH, Wang K, Launer LJ, Smith NL, Chakravarti A, Uitterlinden AG, Wolf PA, Sotoodehnia N, Köttgen A, van Duijn CM, Meitinger T, Mueller M, Perz S, Steinbeck G, Wichmann HE, Lunetta KL, Heckbert SR, Gudnason V, Alonso A, Kääb S, Ellinor PT, Witteman JC. Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet. 2009;41:879-881.